Spots Global Cancer Trial Database for A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Official Title: A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Study ID: NCT03544567
Conditions
Interventions
Study Description
Brief Summary: This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
Detailed Description: Oraxol will be administered once daily for 3 consecutive days every week during the Treatment Period from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; Oraxol may be administered from Week 26 onwards.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Texas Oncology, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
Prince of Wales Hospital, Shatin, Hong Kong, , Hong Kong
National Taiwan University Hospital, Taipei City, , Taiwan
Taipei Veterans General Hosptial, Taipei City, , Taiwan
University College London Hospitals NHS Foundation Trust, London, , United Kingdom
The Royal Marsden NHS Foundation Trust, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, Manchester, , United Kingdom
Contact Details
Name: David Cutler, MD
Affiliation: Athenex, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
